IPSS‐R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk‐stratify the patients

The revised International Prognostic Scoring System (IPSS‐R) was recently developed to better assess the clinical outcome of adult patients with myelodysplastic syndrome (MDS). In this study, we aimed to investigate the prognostic impact of this new risk model on 555 MDS patients in Taiwan. Generall...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of hematology 2014-09, Vol.89 (9), p.E142-E149
Hauptverfasser: Yang, Yi‐Tsung, Hou, Hsin‐An, Liu, Chieh‐Yu, Lin, Chien‐Chin, Chou, Wen‐Chien, Lee, Fen‐Yu, Liu, Ming‐Chih, Liu, Chia‐Wen, Tang, Jih‐Luh, Yao, Ming, Li, Chi‐Cheng, Kuo, Yuan‐Yeh, Huang, Shang‐Yi, Ko, Bor‐Sheng, Chen, Chien‐Yuan, Hsu, Szu‐Chun, Lin, Chien‐Ting, Wu, Shang‐Ju, Tsay, Woei, Chen, Yao‐Chang, Tien, Hwei‐Fang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The revised International Prognostic Scoring System (IPSS‐R) was recently developed to better assess the clinical outcome of adult patients with myelodysplastic syndrome (MDS). In this study, we aimed to investigate the prognostic impact of this new risk model on 555 MDS patients in Taiwan. Generally, the IPSS‐R could discriminate MDS patients regarding risk of leukemia evolution and overall survival in our cohort and it further refined prognostic stratification in all IPSS risk categories. However, we could not find the inter‐group difference between IPSS‐R very low and low risk subgroups in both leukemia‐free survival (LFS) and overall survival (OS). IPSS‐R couldn't distinguish the prognosis between very good and good and between good and intermediate risk cytogenetic categories in OS, and between very good and good and between intermediate and poor cytogenetic‐risk categories in LFS, either. On the other hand, incorporation of monosomal karyotype (MK) into IPSS‐R could further stratify MDS patients with higher‐risk IPSS‐R (intermediate, high and very high risk) into four groups, rather than three groups, with different OS (P 
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.23765